|
rs2155222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The findings indicate the functionality of the PrCa death-predisposing SNPs rs143975731, rs12277366, rs2155225, and rs2155222 as DGAT2 regulators in prostate tumors.© 2016 Wiley Periodicals, Inc.
|
27113481 |
2016 |
|
rs16861209
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs182052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs266729
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs7639352
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs17366568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs3774261
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
|
rs148609049
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03-2.36).
|
30157291 |
2018 |
|
rs137852578
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The gene expression profile of AR-E231G prostate tissue from 12-week-old mice was compared to an equivalent profile from mice expressing the AR-T857A receptor variant (analogous to the AR-T877A variant in LNCaP cells), which do not develop prostate tumors.
|
22275114 |
2012 |
|
rs137852578
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Human LNCaP cells, extensively used as a model for androgen-dependent prostate tumor, express the androgen receptor (AR) mutant T877A promiscuously transactivated by estrogens and other ligands, which may further facilitate cancer progression.
|
12391264 |
2002 |
|
rs1057519864
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance.
|
28209757 |
2017 |
|
rs137852581
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CWR22Rv1 (22Rv1) is an androgen-responsive human prostate carcinoma cell line derived from a primary prostate tumor that expresses mutant (H874Y) androgen receptors (AR) and secretes low levels of prostate specific antigen (PSA).
|
15249132 |
2004 |
|
rs976306779
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo.
|
18452169 |
2008 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency.
|
19079609 |
2008 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency.
|
19079609 |
2008 |
|
rs28909982
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo.
|
16835864 |
2006 |
|
rs587782480
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo.
|
16835864 |
2006 |
|
rs786202601
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo.
|
16835864 |
2006 |
|
rs375118292
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion.
|
24796539 |
2014 |
|
rs1571801
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of the distribution of these SNPs among 1032 prostate cancer patients and 571 control subjects of European descent indicated that one, rs1571801, located in the DAB2IP gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive prostate cancer (one-sided P value = .004).
|
18073375 |
2007 |
|
rs121913430
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs746001963
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion.
|
24796539 |
2014 |
|
rs138213197
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours.
|
29259341 |
2017 |
|
rs138213197
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
|
28186998 |
2017 |
|
rs138213197
|
|
|
0.030 |
GeneticVariation |
BEFREE |
PSA testing, six-core biopsy, genetic counselling and mutation analysis for French Canadian founder mutations in the BRCA1 and BRCA2 genes, histopathological review of tumour tissue from family members, examination of loss of heterozygosity at the BRCA2 gene locus, immunohistochemistry to determine the expression of the ERG nuclear oncoprotein in prostate tumours, genotyping with eight selected risk-associated single nucleotide polymorphisms, Doppler ultrasonography of the leg, CT of the abdomen and pelvis with intravenous and oral contrast, chest CT with intravenous contrast for the assessment of metastatic prostate cancer, genetic testing for the G84E variant in the HOXB13 gene.
|
23318356 |
2013 |